Reviews
Evidence Is Insufficient to Show MPNST Surveillance Improves Outcomes in NF1: Review
Sudarshawn Damodharan and James TonsgardFamilial Cancer

Malignant peripheral nerve sheath tumor (MPNST) represents the leading cause of cancer-related mortality in neurofibromatosis type 1 (NF1), carrying an estimated lifetime risk of 8% to 15% and a five-year survival rate below 50% in most series. Imaging surveillance, primarily using whole-body magnetic resonance imaging (WB-MRI), is frequently utilized under the premise that identifying premalignant or early malignant lesions enables curative surgical resection. To synthesize the underlying evidence, this systematic review conducted under PRISMA 2020 guidelines searched MEDLINE, EMBASE, Cochrane CENTRAL, clinical trial registries, and conference proceedings from 2000 through July 2026.
The review identified 16 eligible records: six surveillance-impact or natural-history cohorts, five imaging diagnostic-accuracy studies, two investigational cell-free DNA studies, and three contextual records (a clinical guideline, a prognostic meta-analysis, and a registered protocol). Due to limited and heterogeneous data, a quantitative meta-analysis was not feasible, and primary outcomes could not be analyzed quantitatively. Comparative incidence data were limited to a single retrospective cohort evaluated against expected population-based rates. Among imaging cohorts, one retrospective study linked 91% of MPNSTs to pre-existing distinct nodular lesions. In symptomatic referral cohorts, diffusion-weighted MRI and FDG-PET identified malignancies with high sensitivity, though specificity varied according to threshold criteria. Harms associated with surveillance were inconsistently documented across reports. Based on GRADE methodology, certainty of evidence was rated low for diagnostic accuracy and very low for surveillance impact and harms, indicating that current literature is insufficient to establish whether routine surveillance improves patient outcomes.
Key Takeaways
- In a retrospective imaging cohort, 91% of malignant peripheral nerve sheath tumors were traced to a pre-existing distinct nodular lesion.
- Diffusion-weighted MRI and FDG-PET discriminated benign from malignant lesions with high sensitivity but threshold-dependent specificity in symptomatic referral cohorts, with GRADE certainty rated as low for diagnostic accuracy and very low for surveillance impact and harms.
Read the original sourceFamilial Cancer
